Palatin Technologies Reports Revenue Surge and Improved Financial Position for Six Months Ended December 31, 2025

Palatin Technologies, Inc. reported its financial results for the three and six months ended December 31, 2025, revealing a significant increase in revenue driven by a collaboration agreement with Boehringer Ingelheim. The company recognized $116,036 in revenue for the three months and $8,963,586 for the six months, compared to no revenue in the same periods of the previous year. This revenue surge is attributed to an upfront payment and milestone achievements under the agreement, which focuses on developing melanocortin receptor-targeted peptides for retinal diseases.

Despite the revenue increase, Palatin's operating expenses also rose, with total operating expenses reaching $7,444,584 for the three months and $11,631,081 for the six months, compared to $2,611,323 and $10,376,008 in the respective periods of 2024. Research and development expenses were $4,319,767 for the three months and $6,845,533 for the six months, reflecting increased investment in the company's MCR programs. The net loss for the three months was $7,263,861, compared to a loss of $2,442,482 in the prior year, while the six-month net loss was $2,586,327, down from $10,266,131.

Palatin's balance sheet showed a substantial improvement in liquidity, with cash and cash equivalents increasing to $14,476,162 as of December 31, 2025, up from $2,564,265 at the end of June 2025. Current liabilities decreased to $6,332,648 from $8,010,030, indicating a stronger financial position. The company’s stockholders' equity improved significantly, moving from a deficiency of $4,777,045 to a positive equity of $11,466,019, primarily due to equity financing and warrant exercises.

Strategically, Palatin has made notable advancements, including the licensing agreement with Boehringer Ingelheim and a sublicense agreement with Altanispac Labs for PL9643, an MCR1 agonist for dry eye disease. The Altanispac agreement includes non-cash debt cancellation of approximately $3,800,000, which will be recognized as revenue in the upcoming quarter. The company is also focused on advancing its product candidates, particularly in the obesity and rare disease markets, while actively seeking partnerships to facilitate development and commercialization.

Looking ahead, Palatin anticipates continued investment in its research and development programs, with plans for multiple clinical trials in 2026. However, the company acknowledges the inherent risks and uncertainties associated with drug development, including regulatory approvals and market competition. Management remains committed to leveraging its existing capital resources and exploring additional financing options to support its ongoing operations and product development initiatives.